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Summary The present phase 11 trial was undertaken to assess the efficacy and toxicity of a combination of paclitaxel and carboplatin as first-
line chemotherapy in patients with metastatic transitional cell carcinoma of the urothelium. Twenty patients (age range 50-79 years; inclusion
criteria: WHO performance status 0-2. no previous cytotoxic treatment) with metastatic transitional cell carcinoma of the urothelium were
recruited and received cytotoxic treatment with paclitaxel at a dosage of 175 mg m-2 administered over a 3-h infusion and carboplatin given at
an AUC of 5 mg ml- min (according to creatinine clearance) administered every 21 days. A total of 65% of patients achieved remissions
(CR+PR), with CR occurring in 40% of patients. A further 15% of patients experienced stable disease. Remissions occurred after 2.4 ± 0.8
(mean ± standard deviation; range two to four) treatment cycles. The mean duration of responses (CR+PR) was 8.5 ± 5.5 months. After a
mean observation period of 11.4 ± 4.8 months, 16 patients (80%) are alive. Toxicity included alopecia of WHO grade 3 in all patients,
leucopenia of WHO grades 1 and 2 in ten patients, grade 3 in eight and grade 4 in two patients and, finally, severe thrombocytopenia grade 3
in only three patients. Non-haematological toxicity consisted of polyneuropathy of WHO grade 1 in 13 patients and grade 2 in five patients. We
thus conclude that a combination of paclitaxel and carboplatin at the given dosage and schedule constitutes an active, well-tolerated first-line
cytotoxic treatment for patients with metastatic urothelial cancer.
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Treatment of metastatic cancer of transitional cells of the urothe-
lium by cytotoxic chemotherapy has led to marked improvement
in the prognosis ofpatients suffering from this disease. Before the
development of effectixe chemotherapy. survival of patients with
metastatic urothelial cancer rarely exceeded 3-6 months. In
contrast. combination chemotherapy has significantly improved
survival rates bv inducing, remissions in over 70%7 of patients
(Harkeret al. 1985: Sternberg et al. 1985: Logothetis et al. 1990a).
Although a series of combinations of cytotoxic drucs has been
studied. treatment with methotrexate. xinblastine. doxorubicin and
cyclophosphamide (cisplatin) (M-VAC) has become therapy of
choice because of its favourable efficacy (Sternberg et al. 1988.
1989: Loehrer et al. 1992). exver since its development at Memorial
Sloan-Ketterinc Cancer Center in 1983 (Sternberg et al. 1985).
Although cisplatin is thought to be the most active acent of this
combination. M-VAC was found to be superior over single-agent
therapy with this drug (Loehrer et al. 1992). Howxexver. the admin-
istration ofM-VAC can produce a series of side-effects. includincg
mvelosuppression. sepsis. mucositis. peripheral neuropathy and
nephrotoxicity (Loehrer et al. 1992). Amona others. it is mainlv
nephrotoxicitv that prexents the inclusion of many. in particular
elderly. patients uwith advanced urothelial cancer who often haxe
decreased renal function under this treatment protocol. Several
modifications of the standard M-VAC regimen haxe been
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proposed. including the substitution of epirubicin for doxorubicin
to reduce cardiotoxicityr or of carboplatin for cisplatin (Petrioli et
al. 1996) to reduce nephrotoxicity. Moreover. attempts haxe been
made to replace cisplatin by aallium nitrate under the addition of
Xinblastine and ifosfamide (Einhomn et al. 1994).
The adxent of newer cvtotoxic drugs has changed the scenanro
in advanced urothelial cancer. as significant single-drug actixitV
has been reported not only for carboplatin (Mottet-Auselo et al.
1995) but also for agents such as paclitaxel (Roth et al. 1994) as
well as gemcitabine (Pollera et al. 1994: Stadler et al. 1997: xon
der Maase et al. 1997). Confronted wxith the limitations and toxici-
ties of M-VAC chemotherapy outhned aboxe and based upon
earlier studies that hax-e demonstrated impressi-e single-agent
efficacy ofpaclitaxel leading to an objectixve response rate of42%l
(Roth et al. 1994) and good efficacy of carboplatin accompanied
by simultaneous low toxicitx (Waxman and Barton. 1993) in
patients with urothelial cancer. the present investigation was
undertaken. The treatment protocol of the present phase II trial
involxved the combined administration of paclitaxel and carbo-
platin in patients with advanced urothelial cancer and resulted in a
response rate (CR+PR) of 65% xxith relatixely low concomitant
toxicity.
PATIENTS AND METHODS
Patients
The study wxas initiated in June 1995 and conducted according to
the declaration of Helsinki. after haxving been approxed by the
ethical committee of the Medical Faculty and the Unixersitv
Hospital. The study included 20 patients (12 women. eight men)
x ith a mean age of 67 (range 50-79) years suffering from
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metastatic. histologically verified pure transitional cell carcinoma
of the urothelium. Nine patients were older than 70 years. which
was permitted by the protocol that concerned recruitment up to the
age of 79 years (see below). Locations of metastatic disease
included lymph nodes (13 patients). liver (three patients). lung
(four patients) and the skeleton (tw-o patients). Also included xwere
patients in whom lung, metastases occurred simultaneously xith
metastases to lymph nodes. in one case. and simultaneously with
liver metastases. in another. Characteristics ofpatients are gixen in
Table 1.
None of the patients was pretreated by cytotoxic chemotherapy
for anv stage of the disease. and all patients were eligible for the
studv and evaluable for efficacy and toxicitx of the chosen thera-
peutic protocol. The current report covers a mean obserxation
period of 11.4 ± 4.8 months.
Inclusion criteria
Inclusion cnrteria consisted ofhistologically x-erified carcinoma of
the urothelium at the time ofdiagnosis. metastases to lymph nodes
and/or inner organs verified by biopsy and/or computerized
tomography (CT). performance status WHO 0-1 (Karnofsky
> 60). age 18-79 years. creatinine clearance > 30 ml min-' and
a signed patient consent to participate in the study.
Exclusion criteria
Exclusion criteria included: prexious treatment of the current
disease with cvtotoxic chemotherapy: local disease only: inade-
quate haematological function (as defined by white blood cells
<3.5 x I091-.granulocy-tes< 1.5 x 191-'.platelets< 100x 1091-'I
the staging procedure being carried out more than 2 weeks before
onset of chemotherapy: second malignancy with the exception of
in situ cerxix cancer or adequately treated basal cell or squamous
cell carcinoma of the skin: history of atrial or ventricular arrhyth-
mias and/or history of congestixe heart failure (exen if medically
controlled): history of clinical and electrocardiographically docu-
mented mvocardial infarction: and pre-existing motor or sensory
neurotoxicity >grade 1. according to WHO criteria (sexere paraes-
thesia and/or mild weakness or worse). Finally. other exclusion
criteria included: actixe infection or any other serious underlying
medical condition that would impair the ability of the patient to
receive protocol treatment: altered mental status that would
prohibit the understanding and giving of informed consent: preg-
nancy and breast feeding: severe hepatic dysfunction (bilirubin
and/or transaminases > 1.25 x upper limits of normal): and creati-
nine clearance <30 ml mmn-'
Cytotoxic therapy
Dose andschedule
Paclitaxel (175mg m- body surface) was gixen by a 3-h contin-
uous infusion subsequently followed by carboplatin given at an
AUC of 5 mg ml-' mmn according to creatinine clearance on day 1
of a , 1-day cycle. This combination has been shown to be safe in
previous inxestigations (Spencer et al. 1994).
Supportive therapy
Antianaphylactic drug therapy consisting of cimetidine. diphen-
hydramine and dexamethasone was given before taxol treatment.
and standard antiemetic medication was administered
Table 1 Patients charactenstics
Characteristics Number of
patients
Age (years)
<69 11
>70 9
Sex
Male 8
Female 12
Performance status (WHO)
0 10
1 10
Sites of metastases
Lymph nodes 13
Liver 3
Lung 4
Bones 2
Multiple sites 2
Table 2 Responses in patients with metastases in different locations
Location CRF PR SD PD
Lymph nodes 7 3 2
Liver 1 - - 1
Lung - 2
Lung + ymph nodes - 1
Lung + liver - - - 1
Bones - - 1 1
aNumber of patients achieving compJete remission (CR), partal remission
(PR). stable disease (SD) or experiencing progressive disease (PD).
Table 3 Treatment-associated toxicity in 20 assessable patientsa
WHO
I 11 Ill IV
Allpatients
Leucopenia 3 7 8 2
Thrombocytopenia 0 0 3 0
Alopecia 0 0 20 0
Polyneuropathy 13 5 0 0
Patients > 70years (n =9)a
Leucopenia 1 3 4 1
Thrombocytopenia 0 0 2 0
Alopecia 0 0 9 0
Polyneuropathy 4 3 0 0
aAll patients included in the trial were assessable fortreatment-associated
toxicity.
Evaluation ofpatients
Before treatment was started. patients w-ere stagedaccording, to the
TNM classification for urinary bladder cancer. The following
procedures were furthermore performed: obligatory - physical
examination, chest radiography. laboratorv tests. sonography of
the liver, total body bone scan. CT scan. intravenous pyelography:
optional - barium enema/sigmoidoscopy. site-specific ultrasound.
CT or magnetic resonance imaging. biopsy. urine cytolooy, bone
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radiography in case of hot spots in total body bone scan.
Responses and toxicities were assessed before each treatment
cycle with chemotherapy being administered in 21-day intervals.
Furthermore, a complete obligatory diagnostic work-up was
performed every other treatment cycle.
Duration oftherapy
After the documentation of clinical complete remission (CR), two
additional cycles ofcytotoxic chemotherapy were administered. In
case ofstable disease (SD) or partial remission (PR). a total ofsix
cycles were given. Documented progression of disease according
to WHO criteria resulted in discontinuation of the treatment
protocol.
0 5 10 15 20
Months
FIgure 1 Overal survival (n= 20). No. of pabents alive, 16; no. of patents
dead, four
in whom the frequency and severity of side-effects did not differ
Statistical analysis significantly from that in youngerpatients (P> 0.05 respectively).
Data are given as mean ± standard deviation. Statistical calculation
were carried out using the log-rank test (overall survival) or chi-
square test (toxicity), both performed with the BMDP-PC program
package using a level ofsignificance of0.05.
RESULTS
Response totreatment
After a mean follow-up of 11.4 ± 4.8 months. 8 (40%) out of 20
patients have achieved complete remission (CR) and five (25%)
partial remission (PR), resulting in an overall response rate
(CR + PR) of 65%. Moreover, three patients (15%) have experi-
enced stable disease (SD). The remaining four patients (20%) had
progressive disease despite the treatment. The mean number of
treatments needed to achieve responses was 2.4 ±0.8 (range two to
four). No difference in the number of ratment cycles needed to
achieve responses was found between patients with CR (2.4 ± 0.7)
and PR (2.4 ±0.8). The mean number oftreatment cycles adminis-
tered was 5.8 ± 0.7 (range 4-6) in patients with CR and 4.4 ± 0.9
(range 3-6) in patients with PR. The duration of responses was
8.5 ± 5.5 (range 1.1-14.9) months in patients with achieved CR
and 7.1 ± 4.2 (range 2.3-11.7) months in patients with PR.
Figure 1 shows a Kaplan-Meier plot for recurrence or progres-
sion of disease. In a detailed analysis, no significant difference in
overall survival was found between patients < 69 (9 of 11 patients
alive) and > 70 years (seven of nine patients alive; P > 0.05) and,
interestingly, between patients with various responses to treatment
(CR: seven ofeight patients alive; PR: four of five patients alive;
P>0.05).
Response according to lation of etasta
Table 2 shows the rate ofresponses in dependence upon the loca-
tion of metastases. It is noteworthy that 10 out of 12 patients with
exclusively lymph node metastases achieved response (CR + PR).
Treatmet-associated toxicity
Treatment-associated toxicity including polyneuropathy, leuco-
penia and thrombopenia was generally low. The only exception
was alopecia grade 3 (WHO), which was experienced in all 20
patients. A detailed description of toxicities is given in Table 3.
Low teataent-associated toxicity was also observed in nine
patients >70 years who were also analysed separately (Table 3) and
Duration of remissions and survival
After a mean observation period of 11.4 ± 4.8 (range 4-17)
months. 16 out of 20 patients (80%) are alive. whereas the
remaining four patients have died as a result of progressive carci-
noma. Thus, 82.5% of patients have experienced an overall
survival of9.1 months (Figure 1). Seven patients have remained in
CR for a mean duration of9.1 (range 1.3-14.9) months, including
one patient with livermetastases (Table 2) whose duration ofCR is
7.5 months at the time ofpreparation ofthe manuscript.
DISCUSSION
Cytotoxic treatment consisting of a combination of methotrexate,
vinblastine, doxorubicin and cisplatin (M-VAC) has proved to
represent effective tatment for metastatic urothelial cancer by
primarily leading to responses in 72% (36% CR) of 121 assessable
patients (Stemnberg et al, 1989). In further trials, responses were
observed in 42-57% (CR 13-19%) ofpatients (Chong et al, 1987;
Hillcoat et al, 1989; Tannock et al, 1989; Igawa et al, 1990;
Boutan-Laroze et al, 1991). An intergroup phase HI study resulted
in a response rate of 39% (CR 13%) of patients whose median
survival was 12.5 months (Loehrer et al. 1992). This latter trial
also addressed the question of the importance of single-agent
therapy with cisplatin (70 mg m- body surface), which has been
discussed to be mainly responsible for the good efficacy of the
entire regimen. However, responses achieved in the cisplatin arm
were only 12% (CR 3%; Loehrer et al. 1992). Further attempts to
increase the efficacy of M-VAC by an increase in dose intensity
through the inclusion of colony-stimulating factors were unsuc-
cessful (Logothetis et al, 1990b; Seidman et al. 1993). Although
remaining the tratment of choice in patients with advanced
urothelial cancer, M-VAC is hampered by. at times, high toxicity
(Stemberg et al, 1989; Logothetis et al, 1990b; Loehrer et al,
1992). Thus, with the introduction of newer cytostatic drugs,
including gemcitabine and paclitaxel, the possibility of increasing
efficacy with low concomitant reatmnt-associated toxicity had to
be re-examined (Pollera et al, 1994; Roth et al, 1994). Setting out
from the concept that the antimicrotubular agent paclitaxel, which
had proved to be effective in a series of tumours in vivo (Ozols,
1995) and against human bladdertumourcell lines in vitro (Rangel
et al, 1994), an Eastern Cooperative Oncology Group trial tested
for the efficacy of paclitaxel administered to 26 patients with
metastatic urothelial cancer in a dose of 250 mg m-2 over 24 h
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(Roth et al. 1994). Responses reached 42% (CR 27%. PR 15%l).
and cvtotoxic treatment w-as relativelv well tolerated: however.
because of the high dose of paclitaxel. the protocol had to include
granulocy-te colony-stimulating factor. In an attempt to further
ameliorate these findings. while trying to keep toxicity low in a
population of patients w-ith metastatic urothelial cancer. w-hich
because of epidemiological reasons often consists of elderly
persons with reduced organ function as a result of advanced age.
we have tested for the efficacy and toxicity of a combination of
paclitaxel in a louwer dose under the addition ofcarboplatin. w-hich
has also been shown to exert sinale-aaent activity in advanced
urothelial cancer (Mottet-Auselo et al. 1995). The present study
population. which included patients of up to 79 years. responded
very favourably (CR + PR 65%: CR 40%7s) to the combination of
these drugs: responses were 2enerallv achieved w-ithin a relatively
short time period and after the administration of a mean of 2.4
(range two to four) treatment cycles. w-hile the duration of
responses w-as 8.5 ± 5.5 months. Of the patients. 80%c are alive
after a mean observation period of 11.4 ± 4.8 months. thus
supporting the concept that the combination of paclitaxel and
carboplatin should be at least as effective as M-VAC in such trials
that have shown its best efficacy. Similar to trials testing for the
efficacy of M-VAC (Loehrer et al. 1992). prognostically
favourable variables for response to the present treatment were
metastases to lymph nodes. Furthermore. the good performance
status (0-1 ) of our patients might have contributed to the results
(Loehrer et al. 1992). Finallv. age was not a prognostic factor in
the present analysis. as the response to treatment was identical in
patients < 69 and > 70 years. Comparing our data w-ith previous
phase II trials of single-agent paclitaxel (Roth et al. 1994).
responses in the present study w-ere higher (65%c vs 42%). w-ith a
higher frequency ofCRs (40%c vs. 27%c) in populations ofpatients
similar in number (20 vs 26). thus suggesting that the results
obtained in the present trial were most probably not related to the
administration of paclitaxel alone. M-VAC polychemotherapy has
been shown to produce frequent treatment-associated side-effects.
including myelotoxicity in 76%7c. nephrotoxicity (grades 3 and4) in
7%7. mucositis in 17% and polneuropathv in 5%s of 126 patients
(Loehrer et al. 1992). In contrast. in the present trial. mvelotoxicitv
w-as infrequent and severe polyneuropathv ofgrades 3 or 4 was not
encountered. It is important to stress that patients over the age of
70 -ears did not experience significantly increased toxicity
compared w-ith younger patients. thus making the protocol also
applicable for an older patient population with advanced urothelial
cancer. We thus conclude that a combination of paclitaxel and
carboplatin constitutes effective treatment of advanced urothelial
cancer and is well tolerated.
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